Eurosurveillance - Volume 10, Issue 9, 01 September 2005

Between 24 February and 26 April 2004, Västra Götaland county in Sweden reported 42 cases of suspected mumps. A descriptive study of the cases was undertaken. A questionnaire was administered by telephone and vaccine effectiveness was calculated using the screening method. Seventy four per cent (31/42) of the suspected cases were interviewed by telephone. Eight out of the 42 serum samples were positive or equivocal for mumps IgM by ELISA. Mumps virus genome was identified in 21/42 (50%) saliva samples. Eleven were selected for sequencing and all were confirmed to be mumps virus. Cases were predominantly from 2 small towns. Eighteen out of 19 cases that developed bilateral swelling could be linked to one small town. The median age of interviewed cases was 43 years (range 5 to 88). Six cases were admitted to hospital, 5 of which were older than 30 years. The highest incidence occurred in the 35 to 44 years age group. Vaccine effectiveness was estimated to be 65% for 1 dose and 91% for 2 doses. This descriptive study shows the increasing age of mumps cases with increasing vaccine coverage. Vaccine effectiveness was particularly high for 2 doses. Second-dose uptake must be ensured, as primary vaccine failure is well documented in mumps. Stronger precautions must be taken to avoid pools of susceptible older individuals accumulating due to the increased risk of complications.

The purpose of this study was to provide evidence about the existence of a coxsackie B outbreak in Greece in 2002 by comparing data of laboratory confirmed coxsackie B recent infections in northern Greece between 1998-2001 with data from 2002. The infections were confirmed serologically, using the indirect immunofluorescence method detecting IgM antibodies for coxsackie B1-B6 viruses. Sera from 2701 patients residents of northern Greece who were suspected to be suffering from coxsackie B virus infections were examined: 2056 between 1998 and 2001, and 645 in 2002. The comparison between the results of laboratory confirmed cases and data available at the laboratory between the two periods showed that: - The total number of patients examined per year was higher in 2002 (645 versus an annual average of 514 in 1998-2001). - The proportion of laboratory confirmed recent infections was lower in 2002 (27.8% versus 32.7%) and the estimated incidence was 0.66/10 000 for 2002 and 0.32-0.84/10 000 for 1998-2001. - The age distribution differed: the proportions of cases in children versus cases in adults were reversed in 2002 compared with 1998-2001, with a higher proportion among children in 2002. The difference between the two periods was statistically significant. Children aged 3-5 years were the age group most affected in 2002. - Seasonal distribution remained the same for both periods (peaks in spring and autumn). In 2002, three fatal cases occurred in April, but no deaths were reported in 1998-2001. - The clinical syndromes involved also differed: cases of respiratory infections, mainly pneumonia, rose from 5.75% to 24.3% in children in 2002 and cases of myopericarditis rose in adults from 13% in 1998-2001 to 29.5% in 2002. The last finding, combined with the involvement of the media (because of the three fatal cases) and the panic in the general public that followed suggested that an outbreak had occurred, but we conclude that there was no outbreak.

Wound infections due to Clostridium botulinum were not recognised in the UK and Republic of Ireland before 2000. C. botulinum produces a potent neurotoxin which can cause paralysis and death. In 2000 and 2001, ten cases were clinically recognised, with a further 23 in 2002, 15 in 2003 and 40 cases in 2004. All cases occurred in heroin injectors. Seventy cases occurred in England; the remainder occurred in Scotland (12 cases), Wales (2 cases) and the Republic of Ireland (4 cases). Overall, 40 (45%) of the 88 cases were laboratory confirmed by the detection of botulinum neurotoxin in serum, or by the isolation of C. botulinum from wounds. Of the 40 cases in 2004, 36 occurred in England, and of the 12 that were laboratory confirmed, 10 were due to type A. There was some geographical clustering of the cases during 2004, with most cases occurring in London and in the Yorkshire and Humberside region of northeast England.

An outbreak of 49 cases of tinea corporis gladiatorum due to Trichophyton tonsurans infection occurred in a high level judo team of 131 members in Orléans, central France, between October 2004 and April 2005. The team was divided into 5 groups: cadet-junior boys (n=44), cadet-junior girls (n=33), male university students (n= 15), female university students (n=21), and a group called ‘pôle technique’ made up of high level judokas who have finished academic study (n=18). The outbreak involved 86% of the cadet-junior boys, but only 6 men in the ‘pôle technique’ (33%) and only 5 of the 69 other team members (7%) (cadet-junior girls and university students). We describe the outbreak and the results of a survey that found a known risk factor for the ‘pôle technique’: sharing an electric hair shaver. Personal hygiene practices were found to be very good among the cadet-junior boys. The high attack rate in this group may be linked to the poor shower facilities in the gymnasium where they practiced that led them to have their showers several hours after the end of daily practice.

Several European countries reported outbreaks of severe disease caused by Streptococcus pyogenes in the late 1980s. This marked a departure from the previous decades, where very few such outbreaks were noted. These changes in disease occurrence formed part of a global phenomenon, the reasons for which have yet to be explained. Results of surveillance activities for invasive S. pyogenes infection within Europe over the past fifteen years identified further increases in many countries. However, variations in surveillance methods between countries preclude robust comparisons being made, illustrating the need for a unified surveillance strategy across Europe. This was finally embodied in the Strep-EURO programme, introduced in 2002.

Infection due to Streptococcus pneumoniae (Pneumococcus) (Pnc) is an important cause of invasive clinical manifestations such as meningitis, septicaemia and pneumonia, particularly in young children and the elderly. A 23-valent polysaccharide Pnc vaccine (PPV) has been available for many years and a 7-valent conjugate Pnc vaccine (PCV) has been licensed since 2001 in Europe. As part of a European Union (EU) funded project on pneumococcal disease (Pnc-EURO), a questionnaire was distributed to all 15 EU member states, Switzerland, Norway and the 10 accession countries in 2003 to ascertain current pneumococcal vaccination policy. Twenty three of the 27 target countries, constituting the current European Union (plus Norway and Switzerland), completed the questionnaire. PPV was licensed in 22 of the 23 responding countries and was in the official recommendations of 21. In all the 20/21 countries for which information was available, risk groups at higher risk of infection were targeted. The number of risk groups targeted ranged from one to 12. At least 17 countries recommend that PPV be administered to all those >65 years of age (in three countries, to those over 60 years of age). Thirteen countries had developed national recommendations for PCV in 2003. No country recommended mass infant immunisation at that time, but rather targeted specific risk groups (between 1 and 11), particularly children with asplenia (n=13) and HIV infection (n=12). PCV use was restricted to children under two years of age in seven countries, and in four countries to children under five years of age. Future decisions on use of pneumococcal vaccines in Europe will be decided on the basis of several factors including: local disease burden; the predicted impact of any universal programme, particularly the importance of serotype replacement and herd immunity (indirect protection to the unvaccinated population); the effectiveness of reduced dose schedules, and vaccine cost. Indeed, at least one country, Luxembourg, has since implemented a universal infant PCV immunisation policy.

In a recent edition of Eurosurveillance Monthly, Gonçalves and colleagues reported that outbreaks of a rash illness in a kindergarten, primary and secondary school in the local health area of Braga in northern Portugal were due to human parvovirus B19 [1]. Although human parvovirus was suspected clinically, laboratory investigations were undertaken to exclude both measles and rubella as the cause of the outbreak, given that Portugal is approaching measles elimination. The authors noted that human parvovirus has been reported as a cause of rash illness, potentially as a differential diagnosis for measles and rubella, in developing and developed countries [1].

In response to the recent report of school outbreaks of parvovirus B19 infection in Portugal [1], Heath Kelly and Jennie Leydon of the Western Pacific Regional Measles Laboratory, have echoed the call for parvovirus B19 tests to be included in measles and rubella surveillance

We are grateful for the comments provided by Kelly and Leydon, and Bernard J Cohen. They seem to share our previously expressed opinion that ’in the context of measles and rubella elimination programs, study protocols should include data collection procedures and laboratory tests able to confirm or discard the diagnosis of B19 infections.’ [1]. They have provided a useful commentary with relevant information and references.